Non-interventional, 5-year retrospective data of home parenteral nutrition in patients with benign chronic intestinal failure: Analysis of an Italian nurse registry (SERECARE II).

Objective: This study is an assessment of home parenteral nutrition service performance and safety and efficacy outcomes in patients with benign chronic intestinal failure.
Methods: This is a retrospective, non-interventional, and multicenter study. Data were collected by trained nurses and recorded in a dedicated registry (SERECARE).
Results: From January 1, 2013 to June 30, 2018, data from a total of 683 patients with benign chronic intestinal failure were entered in the registry. Patients included 208 pediatric (53.8% male; median age = 4.0 y) and 475 adult (47.6% male; median age = 59.0 y) participants. On average, patients were visited 5.4 ± 4.5 times and received 1.4 ± 0.8 training sessions. Retraining was not common and mostly due to change of therapy or change of caregiver. Of 939 complications, 40.9% were related to the central venous catheter and were mostly infectious (n = 182) and mechanical (n = 187). The rate of infectious and mechanical complications per 1000 catheter days decreased over 5 y (0.30-0.15 and 0.33 -0.19, respectively). The rate of complications per 1000 catheter days and the mean complications per patient were higher in pediatric than in adult patients. The hospitalization rate was 1.01 per patient throughout the study period. These data were similar to those registered in a previous study period (2002-2011) (n = 1.53 per patient). Changes over time in the efficacy variables were mostly small and non-significant.
Conclusions: This study confirms the importance of setting up and maintaining structured registries to monitor and improve home parenteral nutrition care. Safety outcomes have improved over the years, most likely due to the underlying efficient nursing service.
Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: F. W. G.: personal fees from Takeda and Baxter, during the conduct of the study; A. D.: none; P. G.: grants from Baxter, outside the submitted work; U. A.: none; S. A.: none; T. C.: none; D. E.: none; M. G.: none; A. L.: personal fees from Nutricia, Nestlé, and Takeda, outside the submitted work; A. M.: none; S. M.: none; F. D. M.: none; N. R.: none; A. S. S: none; L. P.: grants from Baxter, B. Braun, Fresenius Kabi, and Takeda, outside the submitted work; and A. D. F.: personal fees from Baxter, during the conduct of the study, and personal fees from Fresenius Kabi, outside the submitted work.
(Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.)